Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 3751925–1936 (2016).
Google Scholar
Hortobagyi, G. N. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann. Oncol. 291541–1547 (2018).
Google Scholar
Johnston, S. et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. npj Breast Cancer 55 (2019).
Google Scholar
Tripathy, D. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 19904–915 (2018).
Google Scholar
Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17425–439 (2016).
Google Scholar
Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 362465–2472 (2018).
Google Scholar
Sledge, G. W. Jr. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 352875–2884 (2017).
Google Scholar
Sledge, G. W. Jr. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2− negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol. 6116–124 (2020).
Google Scholar
Hortobgy, GN et al. Overall survival with ribociclib plus letrozole in advanced breakd breaker cancer. N. Engl. J. Med. 386942–950 (2022).
Google Scholar
Slamon, D. J. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N. Engl. J. Med. 382514–524 (2020).
Google Scholar
Lu, Y. S. et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2− advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin. Cancer Res. 28851–859 (2022).
Google Scholar
van Ommen-Nijhof, A. et al. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer—the SONIA study: study protocol for a randomized controlled trial. BMC Cancer 181146 (2018).
Google Scholar
Sonke, G. S. et al. Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer. Nature 636474–480 (2024).
Google Scholar
Wang, R. et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy. Breast 76103738 (2024).
Google Scholar
Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545446–451 (2017).
Google Scholar
Belic, J. et al. Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach. Clin. Chem. 61838–849 (2015).
Google Scholar
Verschoor, N. et al. Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival. npj Breast Cancer 961 (2023).
Mendelaar, P. A. J. et al. Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. Mol. Oncol. 162086–2097 (2022).
Google Scholar
Isebia, K. T. et al. mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer. Mol. Oncol. 171898–1907 (2023).
Google Scholar
Reichert, Z. R. et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann. Oncol. 34111–120 (2023).
Google Scholar
Di Leo, A. et al. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. npj Breast Cancer 441 (2018).
Google Scholar
Robertson, J. F. R. et al. Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. npj Breast Cancer 711 (2021).
Google Scholar
Heidary, M. et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res. 16421 (2014).
Google Scholar
Liu, B. et al. The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: novel prognostic indexes based on ctDNA. Breast 65116–123 (2022).
Google Scholar
Stover, D. G. et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J. Clin. Oncol. 36543–553 (2018).
Google Scholar
Walter, C. B. et al. Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer. Breast 80104412 (2025).
Google Scholar
de Maar, J. S. et al. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference—a Dutch population-based study from 2008 to 2018. Breast Cancer Res. Treat. 198253–264 (2023).
Google Scholar
Pernas, S., Tolaney, S. M., Winer, E. P. & Goel, S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther. Adv. Med. Oncol. 101758835918786451 (2018).
Google Scholar
Guo, L. et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp. Hematol. Oncol. 123 (2023).
Google Scholar
Santonja, A. et al. Comparison of tumor-informed and tumor-naive sequencing assays for ctDNA detection in breast cancer. Embo mol. With. 15e16505 (2023).
Google Scholar
Klocker, E. V. et al. Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression. Mol. Oncol. 191897–1917 (2025).
Google Scholar
van Dessel, L. F. et al. Application of circulating tumor DNA in prospective clinical oncology trials—standardization of preanalytical conditions. Mol. Oncol. 11295–304 (2017).
Google Scholar
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). EUR. J. Cancer 45228–247 (2009).
Google Scholar
